OpenFold3 Contributors

Achira
"OpenFold3 is poised to deliver a transformation in structure-based drug discovery through open science, open source, and open models. And as the backbone of behind massive data generation efforts like OpenBind and OpenADMET, it will steer the generation of tremendously valuable structural biology datasets that will power a revolution in drug discovery," said John Chodera, CEO of Achira.

Apheris
"OpenFold3 (OF3) is a huge achievement for structural biology: it is fully open-source, and brings engineering reliability and longevity to ensure the model and its infrastructure continue to evolve. That is why, within the AI Structural Biology (AISB) Network, we chose OF3 for our "Federated OpenFold3 Initiative", where multiple pharma partners fine-tune OF3 on their distributed proprietary structural data to further improve its performance on industrial tasks," said Robin Röhm, CEO and Founder of Apheris.

Astex
“Understanding how ligands bind to their target is a critical part of modern drug discovery. The open-source nature of OpenFold3 will enable a broad range of users to develop customised workflows and ultimately accelerate drug discovery programs. The OpenFold consortium provides a great opportunity to collaborate with world-leading scientists from both academia and industry," said Dr. Paul Mortenson, Senior Director of Computational Chemistry and Informatics.

Bayer
“OpenFold3 allows us to fine-tune the model with internal data to accelerate discovery pipelines across our Crop Science and Pharmaceutical Divisions. The open-source nature enables us to incorporate OpenFold3 into our internal innovative pipelines and enables others in the field to build, innovate, and share their work to further accelerate biomolecular AI research for all,” said Christina Taylor, Senior Science Fellow and Computational Molecular Design Lead at Bayer Crop Science and Executive Member of the OpenFold Consortium. “OpenFold3 will enable state-of-the-art modelling of diverse proteins, as well as their interactions with ligands and other biomolecular molecules to accelerate the development of new crop protection molecules and traits,” added Taylor.

Columbia University
“Biopharma companies can now augment OpenFold3 so it’s able to read your data the way you have it structured,” said Columbia University Assistant Professor Mohammed AlQuraishi. “You can essentially make the model fit your data. We think that will lower the barrier to entry.”

Congruence
“Predicting the structure of ligand-bound proteins, especially at allosteric sites, is critical for drug discovery,” said Clarissa Desjardins, CEO at Congruence. “By integrating OpenFold3 into our Revenir pipeline, we will be able to enhance our exploration of novel binding pockets and design molecules that restore protein function. The openness of the model gives our scientists the freedom to innovate at every stage of discovery."

Cyrus Biotechnology
“The launch of OpenFold3 embodies the sharing ethos of the OpenFold Consortium”, said Cyrus Biotechnology Co-Founder and CEO Lucas Nivon, who co-founded the OpenFold Consortium in 2022. One key aim was to pool resources across the industry to minimize overlap in the development of foundational models with the potential for wide use. “Our goal is that OpenFold becomes the standard in academia and industry, similar to how Linux has functioned for tech,” said Nivon. “This is just the beginning.”

"We are very excited at Cyrus to incorporate OpenFold3 into our work of redesigning natural proteins into superior therapeutics. We also can't wait to fine-tune a structure prediction tool using some of our own data," said Yifan Song, Chief Technology Officer of Cyrus Biotechnology.

Dassault Systemes
"Congratulations to the OpenFold team on the launch of OpenFold 3 — a critical milestone in AI-driven drug design. By pushing the boundaries from structure prediction to therapeutic innovation, OpenFold is accelerating the discovery and design of breakthrough medicines. At 3DS BIOIVA, we are proud to work with OpenFold and the community to advance this new era of open, collaborative science," said Jason Benedict, BIOVIA CEO and R&D Vice President.

Dyno Therapeutics
"By advancing open and rigorous protein modeling, OpenFold strengthens the foundation for innovation in gene therapy which directly accelerates Dyno’s fundamental mission to power genetic agency: An individual’s ability take action at the genetic level to live a healthier life," said Sam Sinai, PhD, Co-founder of Dyno Therapeutics.

Harvard
"With OpenFold3, we’re making biomolecular modeling adaptable and extensible: a platform that can learn from new data, integrate into diverse pipelines, and accelerate discovery across biology," said Dr. Nazim Bouatta, scientific co-leader of OpenFold3.

Kiin Bio
"The release of OpenFold3 marks a transformative milestone for the scientific community. Kiin Bio is proud to be part of the consortium that helped deliver this latest release, which will be made available through our Virtual Scientist Platform," said Filippo Abbondanza, CEO of Kiin Bio.

Novo Nordisk
“Being able to predict the structure of a ligand bound to its target has many implications across the R&D value chain, helping to guide the selection of better targets, accelerating molecular design and optimization, and informing patient stratification in the clinic,” said Peter Clark, vice president of Digital Chemistry & Molecular Design at Novo Nordisk and executive member of OpenFold. “Having access to an open-source model that can be used, adapted and advanced by the broader community, serves as a catalyst towards our commitment to delivering better medicines to patients, faster and with reduced cost.”

NVIDIA
“OpenFold3 exemplifies the blueprint for AI-driven science: groundbreaking models that transform how researchers model and design molecules at scale”, said Anthony Costa, Director of Digital Biology at NVIDIA. “With drop-in libraries like cuEquivariance and simplified, flexible deployment via NVIDIA NIM, we provide the scalable and accessible performance that allows any researcher to move from concept to discovery at unprecedented speed,” said Anthony Costa, Directory of Digital Biology at NVDIA.

Open Molecular Software Foundation
"We've taken learnings from our past projects and focused on making OpenFold3 significantly more modular and configurable to a variety of workflows. We've designed it to be a tool that industry and academic researchers alike can plug directly into their own projects, and we're excited to see what the community builds with it," said Jennifer Wei, Ph. D., technical co-leader of OpenFold3.

Outpace Bio
“OpenFold3 brings all of this new functionality and makes it available to everyone,” said Brian Weitzner, Director of computational and structural biology at Outpace Bio, and co-founder of the OpenFold Consortium. “This new model is so powerful and well-architected that it will serve as a foundation model for other protein AI tools to build upon for years to come.”

Pledge Therapeutics
"At Pledge Therapeutics, we’re advancing models that move beyond pattern recognition to learn the underlying physics and energetics of molecular interactions. By anchoring generative AI in experimentally determined structural and biophysical data, we’re designing next-generation therapeutics once considered out of reach. OpenFold’s ethos reflects our belief that accuracy, interpretability, and transparency; not scale alone, will drive the next leaps in AI-driven drug discovery. This represents a rare alignment between open science and industry, and we’re committed to expanding this frontier through shared innovation," said Ali Munawar, CEO of Pledge Therapeutics.

Polaris Quantum Biotech
"We’re thrilled about the new release of OpenFold3—it marks a major step forward in enabling open-source exploration of protein-ligand complexes. At Polaris Quantum Biotech, it empowers our researchers to accelerate drug discovery using cutting-edge, transparent tools," said Kendall Byler, Director of Computational Chemistry at Polaris Quantum Biotech.

SandboxAQ
“SandboxAQ is proud to collaborate with the OpenFold consortium and contribute our AI expertise, industry insights, and proven technologies to enhance the technical capabilities of OpenFold3,” said Andrea Bortolato, VP of Drug Discovery at SandboxAQ. “By democratizing access to cutting edge AI technologies, tools, and data, OpenFold is helping disrupt and transform traditional drug discovery and materials science processes and remove many of the risks and barriers that stifle innovation.”  

Tamarind
"We've had tremendous excitement from our users to use OpenFold3's state-of-the-art co-folding capabilities. We're excited to bring the protocol to the tens of thousands of scientists using Tamarind, including top 10 pharma and leading biotechs. Many have already proposed applications across dozens of therapeutic modalities and industrial applications. OpenFold3 serves as important next step towards programmable biology, and open science!" said Deniz Kavi, CEO of Tamarind.